Status:
WITHDRAWN
Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil
Lead Sponsor:
University of California, Los Angeles
Collaborating Sponsors:
Pfizer
Conditions:
Pulmonary Arterial Hypertension
Idiopathic Pulmonary Fibrosis
Eligibility:
All Genders
Phase:
PHASE4
Brief Summary
Pulmonary Arterial Hypertension (PAH) in the setting of Idiopathic Pulmonary Fibrosis(IPF)is a risk factor for morbidity and mortality in the peri-lung transplant(LT) setting. Currently there is no si...
Detailed Description
The purpose of this study is to evaluate the use of sildenafil in patients with pulmonary fibrosis and PH being considered for lung transplantation. We hypothesize that not only will sildenafil improv...
Eligibility Criteria
Inclusion
- Patients with Idiopathic Pulmonary Fibrosis referred for lung transplantation at our medical center
- Minimal 6 minute walk distance of 50 meters; must be able to conduct supine exercise during heart catheterization
Exclusion
- Non ambulatory
- Prior adverse reaction/allergy to sildenafil or other PDE-5 Inhibitors
- Any other pulmonary vasodilator within one month of enrollment
Key Trial Info
Start Date :
February 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00625079
Start Date
February 1 2007
End Date
December 1 2009
Last Update
May 1 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
David Geffen School of Medicine UCLA
Los Angeles, California, United States, 90095-1690